论文部分内容阅读
目的研究ATAD2在卵巢癌中的表达及预后评判价值。方法首先,通过Oncomine数据库探索ATAD2在卵巢癌中的表达变化;其次,应用在线数据库及分析工具“the KaplanM eier plotter”(KM plotter)数据库探索ATAD2在卵巢癌中的预后评判价值。结果 Oncomine数据库中共有391个涉及不同种类类型肿瘤的研究结果。其中有75个研究结果关于ATAD2表达差异有统计学意义(P<0.05),70个研究结果显示ATAD2的表达增高,5个研究结果显示ATAD2的表达降低。共有两个研究涉及ATAD2在卵巢癌和正常组织中的表达,共647个样本,显示ATAD2在卵巢癌中的表达较正常组织明显增高。另外,KM plotter数据库的分析显示ATAD2mRNA水平与卵巢癌患者的总生存期以及无进展生存期成负相关。结论 ATAD2 mRNA水平在卵巢癌组织中明显增高,并且是卵巢癌的危险因素,其水平越高预后越差。
Objective To study the expression and prognostic value of ATAD2 in ovarian cancer. Methods Firstly, the expression changes of ATAD2 in ovarian cancer were explored by Oncomine database. Secondly, the prognostic value of ATAD2 in ovarian cancer was explored using on-line database and analysis tool “the KaplanMier plotter” database. Results There were 391 studies involving different types of tumors in the Oncomine database. Among 75 studies, ATAD2 expression was significantly different (P <0.05), 70 studies showed that ATAD2 expression increased, and 5 studies showed that ATAD2 expression was decreased. In two studies involving the expression of ATAD2 in ovarian cancer and normal tissues, a total of 647 samples showed that ATAD2 expression in ovarian cancer was significantly higher than that in normal tissues. In addition, analysis of the KM plotter database showed that ATAD2 mRNA levels were negatively correlated with overall survival and progression-free survival in patients with ovarian cancer. Conclusion The level of ATAD2 mRNA is significantly increased in ovarian cancer tissues and is a risk factor for ovarian cancer. The higher the level of ATAD2 mRNA, the poorer the prognosis.